- CSR Summary Not yet available
- Primary Citation Trial has yet to be published
You are not logged in.
Please login to continue selecting trials.
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment181% FemaleN/A% WhiteN/A
Product ClassKinase InhibitorsSponsor Protocol NumberPCYC-1127-CAData PartnerJohnson & JohnsonCondition StudiedNeoplasmsMean/Median Age (Years)N/A
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available